Press Release

17 September 2018

Immunicum AB (publ) Announces Appointment of Pawel Kalinski and Inge Marie Svane to Scientific Advisory Board

Immunicum AB (publ; IMMU.ST) announced today the appointment of leading oncology experts to its Scientific Advisory Board with the addition of Pawel Kalinski, MD, PhD, Vice Chair for Translational Research within the Department of Medicine at Roswell Park Comprehensive Cancer Center, and Inge Marie Svane, MD, PhD, Professor, Head of the Clinical Cancer Research programme, Faculty of Health Sciences, University of Copenhagen, Director, Centre for Cancer Immunotherapy (CCIT), and consultant in Oncology, Herlev University Hospital. Both Scientific Advisory Board members will serve as a strategic resource to Immunicum as the company continues to advance the clinical development of its lead product, ilixadencel.

"We are honored to have such highly specialized experts in the field of immuno-oncology and cell therapy join our Scientific Advisory Board and provide added guidance on our clinical strategy," said Peter Suenaert, MD, PhD, Chief Medical Officer of Immunicum. "We look forward to collaborating with Pawel and Inge Marie as we continue to advance the development of ilixadencel with the goal for it to be included as a key component in future combination treatments for solid tumors."

"Having developed multiple investigator-sponsored INDs that cover dendritic cell therapies and different forms of modulation of tumor microenvironments, I am pleased to contribute my expertise as Immunicum seeks to harness and apply the therapeutic potential of pro-inflammatory allogeneic dendritic cells in patients with cancer," said Pawel Kalinski, who is also Director of Cancer Vaccine and Dendritic Cell Therapies within Roswell Park`s Center for Immunotherapy.

"Immunicum has developed a very unique and promising approach that stands out in the expanding field of immuno-oncology combination therapies and I am impressed with the clinical data the company has generated so far. Having had the experience of developing a range of immunotherapeutic strategies for a broad spectrum of cancer indications and advancing them through Phase I to III clinical trials, I am eager to support Immunicum`s Scientific Advisory Board in actualizing the full, fundamental potential in the company`s lead product candidate and pipeline," added Inge Marie Svane.

Pawel Kalinski is a distinguished MD/PhD researcher with over 30 years of experience in the field of tumor immunology. Dr. Kalinski`s research focuses on cell therapies and the manipulation of tumor microenvironments with a strong focus on the biology of dendritic cells, T cells and tumor microenvironment-associated myeloid cells. Currently, Pawel holds the positions of Vice Chair for Translational Research, Department of Medicine; Director of Cancer Vaccine and Dendritic Cell Therapies, Center for Immunotherapy; Professor of Oncology; and Co-Leader, Tumor Immunology & Immunotherapy (TII) CCSG Program, at Roswell Park Comprehensive Cancer Center in Buffalo, NY, USA. His research has been featured in over 120 international publications. Dr. Kalinski is also a member of several prestigious organizations including the Society for Immunotherapy of Cancer, American Association for Cancer Research, American Society for Clinical Investigation and the American Association of Immunologists and is a member of the editorial board of leading publications in the immuno-oncology field such as OncoImmunology and Journal for Immunotherapy of Cancer.